A Phase 2 clinical trial demonstrated that a single dose of the monoclonal antibody CIS43LS safely protected adults from malaria infection during a six-month malaria season in Mali.
A Phase 1 clinical trial demonstrated that a single dose of the monoclonal antibody CIS43LS safely prevented malaria in individuals exposed to the parasite for up to 9 months.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.